Abstract
Background:
It is thought that growth hormone (GH) therapy success depends on the patient’s adherence to their treatment regimen, but an optimal approach to improve adherence has not yet been established.
Methods:
To evaluate the effect of patient choice of a GH device on adherence to GH therapy, we carried out a retrospective longitudinal study of 46 GH deficient patients (24 boys, mean age of commencing GH therapy: 7.70±3.12 years) treated with recombinant GH therapy for 3 years, either with or without patient choice (n=28, 18, respectively).
Results:
The group comparison study for adherence, which evaluated the frequency of missed injections based on self-report, revealed that patient choice reduced the proportion of patients with low adherence 3 years after commencing GH therapy (33.3%–7.1%, p=0.042). Furthermore, this longitudinal study revealed that the patients with choice yielded significantly greater height standard deviation scores (SDS) (ΔHt SDS: 1.34±0.44 vs. 0.92±0.57, p=0.020) and insulin-like growth factor 1 (IGF-1) SDS (ΔIGF-1 SDS: 2.49±0.75 vs. 1.89±1.13, p=0.038) than those without choice.
Conclusions:
These results indicate that patient choice might improve adherence to GH therapy, which improves the therapeutic effects of GH therapy.
Acknowledgments
We are very grateful to our colleagues at Kawaguchi Municipal Medical Center who assisted us by guiding patients and parents about GH devices.
Author contributions: MG analyzed data and wrote the manuscript. KT designed the study, collected and analysed data, and wrote the manuscript. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Fisher BG, Acerini CL. Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm Res Paediatr 2013;79:189–96.10.1159/000350251Search in Google Scholar
2. Cutfield WS, Lundgren F. Insulin-like growth factor I and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, turner syndrome and born small for gestational age. Horm Res 2009;71(Suppl 1):39–45.10.1159/000178036Search in Google Scholar
3. Wickramasuriya BP, Casey A, Akhtar S, Zia R, Ehtisham S, et al. Factors determining patient choice of device for GH therapy. Horm Res 2006;65:18–22.10.1159/000090375Search in Google Scholar
4. Kapoor RR, Burke SA, Sparrow SE, Hughes IA, Dunger DB, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child 2008;93:147–8.10.1136/adc.2006.114249Search in Google Scholar
5. Japanese Ministry of Health, Labor, and Welfare. Guideline for diagnosis of children with growth hormone deficiency (in Japanese). http://rhhd.info/pdf/001009a.pdf. Published in 2013.Search in Google Scholar
6. Tanaka T, Tachibana K, Shimatsu A, Katsumata N, Tsushima T, et al. A nationwide attempt to standardize growth hormone assays. Horm Res 2005;64:6–11.10.1159/000087746Search in Google Scholar
7. Suwa S, Tachibana K. Standard growth charts for height and weight of Japanese children from birth to 17 years based on a cross-sectional survey of national data. Clin Pediatr Endocrinol 1993;2:87–97.10.1297/cpe.2.87Search in Google Scholar
8. Isojima T, Shimatsu A, Yokoya S, Chihara K, Tanaka T, et al. Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-1) levels in a normal Japanese population using the LMS method. Endocr J 2012;59:771–80.10.1507/endocrj.EJ12-0110Search in Google Scholar
9. Langham S, Kirk J. British society for paediatric endocrinology and diabetes. National audit of patient choice in pediatric GH therapy. Horm Res Paediatr 2011;75:101–5.10.1159/000318784Search in Google Scholar
10. De Pedro S, Murillo M, Salinas I, Granada ML, Martinez M, et al. Variability in adherence to rhGH treatment: socioeconomic causes and effect on children’s growth. Growth Horm IGF Res 2016;26:32–5.10.1016/j.ghir.2015.12.002Search in Google Scholar
11. Hartmann K, Ittner J, Müller-Rossberg E, Schönau E, Stephan R, et al. Growth hormone treatment adherence in prepubertal and pubertal children with different growth disorders. Horm Res Paediatr 2013;80:1–5.10.1159/000351800Search in Google Scholar
12. Bouhours-Nouet N, Gatelais F, Boux de Casson F, Rouleau S, Coutant R. The insulin-like growth factor-I response to growth hormone is increased in prepubertal children with obesity and tall stature. J Clin Endocrinol Metab 2007;92:629–35.10.1210/jc.2005-2631Search in Google Scholar
13. Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, et al. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007;92:2480–6.10.1210/jc.2007-0204Search in Google Scholar
14. Aydın BK, Aycan Z, Sıklar Z, Berberoğlu M, Ocal G, et al. Adherence to growth hormone therapy: results of a multicenter study. Endocr Pract 2014;20:46–51.10.4158/EP13194.ORSearch in Google Scholar
15. Rosenfeld RG, Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 2008;14:143–54.10.4158/EP.14.2.143Search in Google Scholar
Supplemental Material:
The online version of this article offers supplementary material (https://doi.org/10.1515/jpem-2017-0146).
©2017 Walter de Gruyter GmbH, Berlin/Boston